Fda approves abbott's spinal cord stimulation for people living with painful diabetic peripheral neuropathy

The new indication for abbott's proclaim™ xr scs system provides a non-medication option for people with painful diabetic peripheral neuropathy spinal cord stimulation is proven to be more effective than conventional medical management in the treatment of chronic pain1,2 abbott park, ill., jan. 26, 2023 /prnewswire/ -- abbott (nyse: abt) announced today that the u.s. food and drug administration (fda) has approved its proclaim™ xr spinal cord stimulation (scs) system to treat painful diabetic peripheral neuropathy (dpn), a debilitating complication of diabetes.
ABT Ratings Summary
ABT Quant Ranking